Home / Health / FDA Approves First Drug for Rare Genetic Brain Disorder

FDA Approves First Drug for Rare Genetic Brain Disorder

Summary

  • FDA approved Sanofi's Infilbray for rare type 3 Gaucher disease.
  • The oral drug is the first treatment for this specific brain condition.
  • Study showed improved muscle control and cognitive function.

The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi's oral medication, venglustat, now branded as Infilbray. This marks a significant milestone as it is the first approved treatment for a rare genetic condition impacting the brain and nervous system.

Infilbray is indicated for adults and children weighing at least 15 kilograms who have type 3 Gaucher disease. This inherited disorder is characterized by the buildup of fatty substances in the body and brain, affecting neurological functions.

A late-stage study involving 43 patients aged 12 and older confirmed the drug's efficacy. These patients had stabilized symptoms outside the brain and nervous system through enzyme replacement therapy.

Those treated with daily Infilbray for 52 weeks exhibited enhanced muscle control, coordination, and cognitive function. This improvement was noted in comparison to patients receiving bi-weekly enzyme replacement therapy. Gastrointestinal problems and mood alterations were identified as the most frequent side effects.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571